Initial Prostate Biopsy: Development and Internal Validation of a Biopsy-specific Nomogram Based on the Prostate Cancer Antigen 3 Assay

Hansen, Jens; Auprich, Marco; Ahyai, Sascha; Taille, Alexandre de la; Poppel, Hendrik Van; Marberger, Michael; Stenzl, Arnulf; Mulders, Peter F.A.; Huland, Hartwig; Fisch, Margit; Abbou, C.C.; Schalken, Jack A.; Fradet, Yves; Marks, Leonard S.; Ellis, William; Partin, Alan W.; Pummer, Karl; Graefen, Markus; Haese, Alexander; Walz, Jochen; Briganti, Alberto; Shariat, Shahrokh F.; Chun, Felix K.-H.

doi:10.1016/j.eururo.2012.07.030

Cited by 113 publications

(88 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In one study, PCA3 was combined with clinical data in men undergoing an initial prostate biopsy [32] and diagnostic accuracy of PCA3 was compared using receiver operating characteristic curves. These models demonstrated that a PCA3-based nomogram significantly outperformed the clinical models without PCA3.…”

Section: ) [31••]mentioning

confidence: 99%

Screening for Prostate Cancer—Beyond Total PSA, Utilization of Novel Biomarkers

2015

View full text Add to dashboard Cite

Urology has been beset by several major trends that have shifted the entire paradigm for prostate cancer screening. These stem from a backlash against overdiagnosis and overtreatment due to prostate-specific antigen (PSA)-based screening efforts and have led national societies to modify their guidelines. More importantly, the public outcry has shifted the focus of early detection from an effort to diagnose any and all prostate cancers to an effort to diagnose clinically significant prostate cancers at an early stage. This review provides an update on contemporary biomarkers for prostate cancer that may be used to supplement PSA-based screening approaches.

show abstract

Section: ) [31••]mentioning

confidence: 99%

Screening for Prostate Cancer—Beyond Total PSA, Utilization of Novel Biomarkers

2015

View full text Add to dashboard Cite

show abstract

“…In a repeated biopsies environment, multiparametric MRI grading combined with PCA3 score are associated with better PCa detection rates [50,51] and in men eligible for AS, PCA3 can improve the prognostic performance of PRIAS and Epstein criteria for insignificant PCa [52]. Hansen et al [53] proved that the use of PCA3 within nomogram might improve the accuracy of the clinical model by 4.5-7.1% when predicting the risk of harboring PCa at initial biopsy. After its promising initial performance, the nomogram combining established clinical risk factors (age, DRE, prostate volume, PSA) with PCA3 has been successfully validated externally [54].…”

Section: Prostate Cancer Antigen 3 -Replacing Protein Detection With mentioning

confidence: 99%

What Can Be Expected from Prostate Cancer Biomarkers A Clinical Perspective

Zapała

Dybowski²,

Poletajew³

et al. 2017

Urol Int

View full text Add to dashboard Cite

Along with significant advances in prostate cancer biology research, we also observe the rapid development of modern diagnostic tests. New biomarkers are derived to detect disease while it is organ-confined to stratify the risk and to aid clinical decision-making. Majority of these tools have already been validated clinically, but only a few have received premarket clearance and administration approval. Superiority of novel tests is visible not only in improved detection accuracy but predominantly in the assessment of tumour aggressiveness and selection of patients eligible for conservative management. Two factors limiting the clinical implementation of validated biomarker candidates are costs and local availability. For these reasons, currently, their true clinical role starts after routine screening with prostate-specific antigen test. With this review of prostate cancer biomarkers, we attempted to draw general conclusions on clinical perspectives of these novel tools.

show abstract

“…The value cut-off is controversial but adding PCA3 to conventional nomograms for decision making comprising DRE, PSA prostate volume and age increases diagnostic accuracy by 7.1%. 10 Another limitation of PCA3 is that it may not predict aggressive disease. 11 In terms of their use within the NHS, PCA3 and newer tests such as Oncotype Dx and Prolaris are highly restricted because of financial constraints and availability of backhouse technical support, as well as limited robust clinical data supporting the genomic tests.…”

Section: Recent Advances and Current Practicementioning

confidence: 99%